Results 11 to 20 of about 17,663 (255)

Non-vitamin K antagonist oral anticoagulants for heart diseases [PDF]

open access: yesТерапевтический архив, 2017
Non-vitamin K antagonist oral anticoagulants (NОАСs) are highly effective drugs that prevent venous thrombosis and stroke in atrial fibrillation. Their use has difficulties that are associated with the need for laboratory control and with the influence ...
T B Kondratieva, L V Popova, I N Bokarev
doaj   +3 more sources

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants

open access: yesAdvances in Hematology, 2020
Non-vitamin K antagonist oral anticoagulants (NOACs) include thrombin inhibitor dabigatran and coagulation factor Xa inhibitors rivaroxaban, apixaban, edoxaban, and betrixaban.
Mark Terence P. Mujer   +7 more
doaj   +4 more sources

Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome [PDF]

open access: yesRheumatology, 2016
The current treatment of thrombotic APS patients includes long-term anticoagulation with oral vitamin K antagonists (VKAs), with warfarin being the one most commonly used. However, the use of VKAs can be challenging, especially in patients with APS.
SCIASCIA, Savino   +5 more
openaire   +3 more sources

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. [PDF]

open access: yes, 2020
Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ...
Bassand, J-P   +17 more
core   +2 more sources

Effects of oral anticoagulants on bone health (systematic literature review)

open access: yesBolʹ, Sustavy, Pozvonočnik, 2023
Background. Osteoporosis is actually today's problem, as it affects the quality and length of life, and increases the risk of fragility fractures, which leads to significant medical, social, and economic problems.
H.V. Mostbauer   +4 more
doaj   +1 more source

Non-vitamin K antagonist oral anticoagulants for COVID-19 thrombosis

open access: yesJournal of Acute Disease, 2022
Thrombotic complications appear to be a major predictor of death in COVID-19 patients, and multiple studies have shown that anticoagulants can help to improve the outcome.
Adel Khalifa Sultan Hamad
doaj   +1 more source

The year in cardiology: arrhythmias and pacing. [PDF]

open access: yes, 2020
During this last year, there has been much progress with regard to anticoagulant and ablation therapy for atrial fibrillation (AF). Apart from recently issued European Society of Cardiology Guidelines for the management of patients with supraventricular ...
Calkins, H   +4 more
core   +4 more sources

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

open access: yesHellenic Journal of Cardiology, 2021
Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific ...
George Ntaios   +903 more
doaj   +1 more source

Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation [PDF]

open access: yes, 2016
This is an Accepted Manuscript of an article published by Taylor & Francis GroupNon-vitamin K antagonist oral anticoagulants (NOACs) reduce the risk of thromboembolism in patients with atrial fibrillation (AF).
Artman, Benjamin   +8 more
core   +2 more sources

Safety of direct oral anticoagulants in patients with atrial fibrillation and high risk of stroke (review of literature)

open access: yesУчёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, 2020
Review discusses the problem of non-vitamin K antagonist oral anticoagulants safety in patients with non-valvular atrial fibrillation. Bleeding risk assessment while applying anticoagulant therapy, preventive methods for major bleeding (intracranial ...
E. I. Baranova   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy